Zobrazeno 1 - 10
of 400
pro vyhledávání: '"Anna C. Pavlick"'
Autor:
Guilherme Rabinowits, Michael R. Migden, Todd E. Schlesinger, Robert L. Ferris, Morganna Freeman, Valerie Guild, Shlomo Koyfman, Anna C. Pavlick, Neil Swanson, Gregory T. Wolf, Scott M. Dinehart
Publikováno v:
JID Innovations, Vol 1, Iss 4, Pp 100045- (2021)
Cutaneous squamous cell carcinoma is the second most common skin cancer in the United States. Currently, there is no standardized management approach for patients with cutaneous squamous cell carcinoma who develop metastatic or locally advanced disea
Externí odkaz:
https://doaj.org/article/7bfa396119cd430f85368f3066722ea1
Autor:
Paul T. Finger, Anna C. Pavlick
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 7, Iss 1, Pp 1-7 (2019)
Abstract Background Herein, we describe the use of systemic immunotherapy for both locally advanced and metastatic conjunctival melanoma. Current treatments for advanced conjunctival melanoma typically result in poor local control leading to disfigur
Externí odkaz:
https://doaj.org/article/62b4ef4515724f1188634c4d8c4ec4a9
Autor:
Ryan J. Sullivan, Michael B. Atkins, John M. Kirkwood, Sanjiv S. Agarwala, Joseph I. Clark, Marc S. Ernstoff, Leslie Fecher, Thomas F. Gajewski, Brian Gastman, David H. Lawson, Jose Lutzky, David F. McDermott, Kim A. Margolin, Janice M. Mehnert, Anna C. Pavlick, Jon M. Richards, Krista M. Rubin, William Sharfman, Steven Silverstein, Craig L. Slingluff, Vernon K. Sondak, Ahmad A. Tarhini, John A. Thompson, Walter J. Urba, Richard L. White, Eric D. Whitman, F. Stephen Hodi, Howard L. Kaufman
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 6, Iss 1, Pp 1-23 (2018)
Abstract Background Cancer immunotherapy has been firmly established as a standard of care for patients with advanced and metastatic melanoma. Therapeutic outcomes in clinical trials have resulted in the approval of 11 new drugs and/or combination re
Externí odkaz:
https://doaj.org/article/4608673a241f46ca9625955f197bdebe
Autor:
Michael Lattanzi, Joseph Han, Una Moran, Kierstin Utter, Jeremy Tchack, Rachel Lubong Sabado, Russell Berman, Richard Shapiro, Hsin-Hui Huang, Iman Osman, Nina Bhardwaj, Anna C. Pavlick
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 6, Iss 1, Pp 1-10 (2018)
Abstract Background Cancer-testis antigen NY-ESO-1 is a highly immunogenic melanoma antigen which has been incorporated into adjuvant vaccine clinical trials. Three such early-phase trials were conducted at our center among patients with high-risk re
Externí odkaz:
https://doaj.org/article/fd1e2c8d12284a4da542561e33954d18
Autor:
Michael F. Gowen, Keith M. Giles, Danny Simpson, Jeremy Tchack, Hua Zhou, Una Moran, Zarmeena Dawood, Anna C. Pavlick, Shaohui Hu, Melissa A. Wilson, Hua Zhong, Michelle Krogsgaard, Tomas Kirchhoff, Iman Osman
Publikováno v:
Journal of Translational Medicine, Vol 16, Iss 1, Pp 1-12 (2018)
Abstract Background Immune checkpoint inhibitors (anti-CTLA-4, anti-PD-1, or the combination) enhance anti-tumor immune responses, yielding durable clinical benefit in several cancer types, including melanoma. However, a subset of patients experience
Externí odkaz:
https://doaj.org/article/25bad45d849a486cbdacef0da4e5f3a3
Autor:
Omid Hamid, Diwakar Davar, Keisuke Shirai, Benjamin Izar, Charlotte E Ariyan, Michael K Wong, Jason J Luke, Janis M Taube, Anna C Pavlick, Meghan J Mooradian, Douglas B Johnson, Hussein A Tawbi, Tara C Mitchell, Ryan J Sullivan, April KS Salama, Krista M Rubin, Elizabeth I Buchbinder, Sarah A Weiss, Tina J Hieken, Geoffrey T Gibney, Rajan P Kulkarni, J Keith Tolley, Caressa Valdueza
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 11, Iss 10 (2023)
Since the first approval for immune checkpoint inhibitors (ICIs) for the treatment of cutaneous melanoma more than a decade ago, immunotherapy has completely transformed the treatment landscape of this chemotherapy-resistant disease. Combination regi
Externí odkaz:
https://doaj.org/article/f4721e0504094c6083b6710589696855
Publikováno v:
Melanoma research. 32(5)
Checkpoint immunotherapies (CPIs) have improved outcomes for metastatic melanoma patients, with objective response rates to combination ipilimumab and nivolumab of ~58%. Preclinical data suggest that histone deacetylase (HDAC) inhibition enhances ant
Autor:
Drew W. Rasco, Theresa Medina, Pippa Corrie, Anna C. Pavlick, Mark R. Middleton, Paul Lorigan, Chris Hebert, Ruth Plummer, James Larkin, Sanjiv S. Agarwala, Adil I. Daud, Jiaheng Qiu, Viviana Bozon, Michelle Kneissl, Elly Barry, Anthony J. Olszanski
Publikováno v:
Cancer chemotherapy and pharmacology, vol 92, iss 1
Purpose Genomic alterations of BRAF and NRAS are oncogenic drivers in malignant melanoma and other solid tumors. Tovorafenib is an investigational, oral, selective, CNS-penetrant, small molecule, type II pan‑RAF inhibitor. This first-in-human phase
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6be879ecf897194f5e93f0a32cbcfa4d
https://www.repository.cam.ac.uk/handle/1810/350906
https://www.repository.cam.ac.uk/handle/1810/350906
Autor:
Assaf, Berger, Kenneth, Bernstein, Juan Diego, Alzate, Reed, Mullen, Joshua S, Silverman, Erik P, Sulman, Bernadine R, Donahue, Anna C, Pavlick, Jason, Gurewitz, Monica, Mureb, Janice, Mehnert, Kathleen, Madden, Amy, Palermo, Jeffrey S, Weber, John G, Golfinos, Douglas, Kondziolka
Publikováno v:
Journal of Neuro-Oncology. 158:471-480
New therapies for melanoma have been associated with increasing survival expectations, as opposed to the dismal outcomes of only a decade ago. Using a prospective registry, we aimed to define current survival goals for melanoma patients with brain me
Autor:
Tara C. Gangadhar, Giorgos C. Karakousis, Lynn M. Schuchter, Luke Walker, Hussein Tawbi, Jeffrey A. Sosman, Anna C. Pavlick, Ragini R. Kudchadkar, Naomi B. Haas, Ravi K. Amaravadi, Jianhua Zhao, Meghan Buckley, Wanleng Deng, Shujing Liu, Khalida M. Wani, Michael T. Tetzlaff, Jennifer J.D. Morrissette, Phyllis A. Gimotty, Michael A. Davies, Xiaowei Xu, Clinton Yam
Supplementary Table S1. List of antibodies used in reverse phase protein array (RPPA). A table summarizing the antibodies used for RPPA in this study.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::27fd0c780738d48cf0d8590c75b05981
https://doi.org/10.1158/1078-0432.22463004
https://doi.org/10.1158/1078-0432.22463004